The 2015 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC)

Authors

  • Fred Saad Centre Hospitalier de l'Universite de Montreal, Montreal, QC
  • Kim Chi British Columbia Cancer Agency, Vancouver, BC
  • Antonio Finelli University Health Network, Toronto, ON
  • Sebastien Hotte McMaster University, Hamilton, ON
  • Jonathan Izawa London Health Sciences Centre, London, ON
  • Anil Kapoor McMaster University, Hamilton, ON
  • Wassim Kassouf McGill University Health Centre, Montreal, QC
  • Andrew Loblaw Sunnybrook Health Sciences Centre, Toronto, ON
  • Scott North Cross Cancer Institute, Edmonton, AB
  • Ricardo Rendon Dalhousie University, Halifax, NS
  • Alan So University of British Columbia, Vancouver, BC
  • Nawaid Usmani Cross Cancer Institute, Edmonton, AB
  • Eric Vigneault Centre Hospitalier Universitaire de Quebec—Pavillon L’Hotel-Dieu, Quebec City, QC
  • Neil Eric Fleshner University Health Network, Toronto, ON

DOI:

https://doi.org/10.5489/cuaj.2526

Keywords:

castration-resistant prostate cancer

Abstract

Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance of optimizing the use of these agents, a multidisciplinary team approach is highly recommended.

Downloads

Download data is not yet available.

Author Biographies

Fred Saad, Centre Hospitalier de l'Universite de Montreal, Montreal, QC

Division of Urologic Oncology

Antonio Finelli, University Health Network, Toronto, ON

Division of Urology, Princess Margaret Cancer Centre

Sebastien Hotte, McMaster University, Hamilton, ON

Division of Medical Oncology

Jonathan Izawa, London Health Sciences Centre, London, ON

Divisions of Urology & Surgical Oncology

Anil Kapoor, McMaster University, Hamilton, ON

Division of Urology

Wassim Kassouf, McGill University Health Centre, Montreal, QC

Department of Urology

Andrew Loblaw, Sunnybrook Health Sciences Centre, Toronto, ON

Department of Radiation Oncology, Odette Cancer Centre

Scott North, Cross Cancer Institute, Edmonton, AB

Department of Oncology

Ricardo Rendon, Dalhousie University, Halifax, NS

Department of Urology

Alan So, University of British Columbia, Vancouver, BC

Department of Urologic Sciences

Nawaid Usmani, Cross Cancer Institute, Edmonton, AB

Department of Oncology

Eric Vigneault, Centre Hospitalier Universitaire de Quebec—Pavillon L’Hotel-Dieu, Quebec City, QC

Department of Radiation Oncology

Neil Eric Fleshner, University Health Network, Toronto, ON

Division of Urology, Princess Margaret Cancer Centre

Downloads

Published

2015-04-13

How to Cite

Saad, F., Chi, K., Finelli, A., Hotte, S., Izawa, J., Kapoor, A., Kassouf, W., Loblaw, A., North, S., Rendon, R., So, A., Usmani, N., Vigneault, E., & Fleshner, N. E. (2015). The 2015 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC). Canadian Urological Association Journal, 9(3-4), 90–7. https://doi.org/10.5489/cuaj.2526

Issue

Vol. 9 No. 3-4 (2015): CUAJ April

Section

CUA Guideline

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.

Similar Articles

You may also start an advanced similarity search for this article.